These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2196630)

  • 1. The pharmacotherapy of depressive illness in adolescence: I. An open label trial of imipramine.
    Strober M; Freeman R; Rigali J
    Psychopharmacol Bull; 1990; 26(1):80-4. PubMed ID: 2196630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipramine blood levels and clinical outcome.
    Rigal JG; Albin HC; Duchier AR; D'Aulnay JM; Fenelon JH; Vincon GA; Demotes-Mainard FM
    J Clin Psychopharmacol; 1987 Aug; 7(4):222-9. PubMed ID: 3624505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders.
    Baca E; Garcia-Garcia M; Porras-Chavarino A
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):57-65. PubMed ID: 14687858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
    Schweizer E; Feighner J; Mandos LA; Rickels K
    J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nefazodone in the treatment of severe, melancholic, and recurrent depression.
    Marcus RN; Mendels J
    J Clin Psychiatry; 1996; 57 Suppl 2():19-23. PubMed ID: 8626359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of imipramine in psychotic versus nonpsychotic depression.
    Birkenhager TK; van den Broek WW; Mulder PG; Moleman P; Bruijn JA
    J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect size as a measure of symptom-specific drug change in clinical trials.
    Leon AC; Shear MK; Portera L; Klerman GL
    Psychopharmacol Bull; 1993; 29(2):163-7. PubMed ID: 8290660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness.
    Rabkin JG; Rabkin R; Wagner G
    J Clin Psychiatry; 1994 Mar; 55(3):92-7. PubMed ID: 7915270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD
    Psychopharmacol Bull; 1996; 32(4):659-65. PubMed ID: 8993088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study.
    Bohacek N; Ravic M; Bizière K
    Drugs Exp Clin Res; 1987; 13(7):435-42. PubMed ID: 3308390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.
    Thase ME; Frank E; Mallinger AG; Hamer T; Kupfer DJ
    J Clin Psychiatry; 1992 Jan; 53(1):5-11. PubMed ID: 1737741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials.
    Spielmans GI; McFall JP
    J Nerv Ment Dis; 2006 Nov; 194(11):845-52. PubMed ID: 17102709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine.
    Wells BG; Evans RL; Ereshefsky L; Antal EJ; Lobeck F; Rawls WN; Hamann G; Grimmig J; Smith RB
    J Clin Psychiatry; 1988 Oct; 49(10):394-9. PubMed ID: 3049560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression in children: relationship between plasma imipramine levels and response.
    Preskorn SH; Weller EB; Weller RA
    J Clin Psychiatry; 1982 Nov; 43(11):450-3. PubMed ID: 7174621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern analysis of antidepressant response to fluoxetine.
    Fieve RR; Goodnick PJ; Peselow ED; Barouche F; Schlegel A
    J Clin Psychiatry; 1986 Nov; 47(11):560-2. PubMed ID: 3533909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.
    Thase ME; Kupfer DJ; Jarrett DB
    J Clin Psychiatry; 1989 Oct; 50(10):385-8. PubMed ID: 2676995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD; Shults J
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.